Nabriva Therapeutics PLC – (NASDAQ:NBRV) – Equities research analysts at Wedbush issued their Q1 2019 earnings per share (EPS) estimates for shares of Nabriva Therapeutics in a report released on Tuesday, March 12th. Wedbush analyst R. Driscoll expects that the biotechnology company will post earnings of ($0.31) per share for the quarter.
NBRV has been the topic of several other reports. Zacks Investment Research raised Nabriva Therapeutics from a “hold” rating to a “buy” rating and set a $2.25 target price on the stock in a research report on Tuesday, February 5th. Northland Securities reaffirmed a “buy” rating and issued a $12.50 price objective on shares of Nabriva Therapeutics in a research note on Tuesday. BidaskClub raised Nabriva Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, February 5th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Nabriva Therapeutics in a research note on Wednesday. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $10.22.
Shares of NASDAQ:NBRV opened at $2.86 on Thursday. The stock has a market capitalization of $1.88 billion, a price-to-earnings ratio of -1.75 and a beta of 2.27. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.35 and a current ratio of 7.35. Nabriva Therapeutics has a 52-week low of $1.12 and a 52-week high of $6.05.
In related news, Director Charles A. Rowland, Jr. acquired 53,000 shares of the firm’s stock in a transaction dated Monday, December 24th. The shares were purchased at an average price of $1.31 per share, with a total value of $69,430.00. Following the completion of the purchase, the director now directly owns 53,000 shares of the company’s stock, valued at $69,430. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 2.15% of the stock is owned by company insiders.
A number of institutional investors and hedge funds have recently modified their holdings of NBRV. Jane Street Group LLC bought a new stake in Nabriva Therapeutics during the 4th quarter valued at approximately $29,000. HRT Financial LLC bought a new stake in Nabriva Therapeutics during the 4th quarter valued at approximately $31,000. Two Sigma Advisers LP bought a new stake in Nabriva Therapeutics during the 4th quarter valued at approximately $37,000. Paloma Partners Management Co bought a new stake in Nabriva Therapeutics during the 4th quarter valued at approximately $54,000. Finally, Wedbush Securities Inc. raised its stake in Nabriva Therapeutics by 12.5% during the 4th quarter. Wedbush Securities Inc. now owns 103,550 shares of the biotechnology company’s stock valued at $151,000 after purchasing an additional 11,500 shares during the period. 4.81% of the stock is currently owned by institutional investors.
About Nabriva Therapeutics
Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.
Read More: What is the Gross Domestic Product (GDP)?
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.